摘要 |
<p>Heterocyclic-substituted tricyclics of formula (I) or a pharmaceutically acceptable salt thereof, wherein: the single dotted line represents an optional double bond; the double dotted line represents an optional single bond; n is 0-2; Q is optionally substituted cycloalkyl, heterocycloalkyl, aryl or heteroaryl; Het is an optionally substituted mono-, bi- or tricyclic heteroaromatic group; B is -(CH2)n3-, wherein n3 is 0-5, -CH2-O-, -CH2S-, -CH2-NR<6>-, -C(O)NR<6>-. -NR<6>C(O)-, (a), optionally substituted alkenyl or optionally substituted alkynyl; X is -O- or -NR<6>- when the double dotted line represents a single bond, or X is -OH or -NHR<20> when the bond is absent; Y is =O, =S, (H, H), (H, OH) or (H, C1-C6 alkoxy) when the double dotted line represents a single bond, or when the bond is absent, Y is =O, (H, H), (H, OH), (H, SH) or (H, C1-C6 alkoxy); R<15> is absent when the double dotted line represents a single bond and is H, -NR<18>R<19>, or -OR<17> when the bond is absent; or Y is (A) or (B) and R<15> is H or C1-C6 alkyl; are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds.</p> |